"4.5\tInterakce s jin\u00FDmi l\u00E9\u010Div\u00FDmi p\u0159\u00EDpravky a jin\u00E9 formy interakce"@cs . "Antiepileptika\n\u00DAdaje z klinick\u00FDch studi\u00ED proveden\u00FDch u dosp\u011Bl\u00FDch p\u0159ed uveden\u00EDm p\u0159\u00EDpravku na trh ukazuj\u00ED, \u017Ee levetiracetam neovliv\u0148uje s\u00E9rov\u00E9 koncentrace ji\u017E pod\u00E1van\u00FDch antiepileptik (fenytoin, karbamazepin, kyselina valproov\u00E1, fenobarbital, lamotrigin, gabapentin a primidon) a \u017Ee tato antiepileptika neovliv\u0148uj\u00ED farmakokinetiku levetiracetamu.\nStejn\u011B jako u dosp\u011Bl\u00FDch nen\u00ED u d\u011Bt\u00ED u\u017E\u00EDvaj\u00EDc\u00EDch levetiracetam do d\u00E1vky 60 mg/kg/den d\u016Fkaz o klinicky v\u00FDznamn\u00FDch interakc\u00EDch l\u00E9\u010Div\u00E9ho p\u0159\u00EDpravku.\nRetrospektivn\u00ED hodnocen\u00ED farmakokinetick\u00FDch interakc\u00ED u d\u011Bt\u00ED a dosp\u00EDvaj\u00EDc\u00EDch s epilepsi\u00ED (4-17 let) potvrdilo, \u017Ee p\u0159\u00EDdatn\u00E1 l\u00E9\u010Dba peror\u00E1ln\u011B u\u017E\u00EDvan\u00FDm levetiracetamem neovliv\u0148uje s\u00E9rov\u00E9 koncentrace sou\u010Dasn\u011B pod\u00E1van\u00E9ho karbamazepinu a valpro\u00E1tu v ust\u00E1len\u00E9m stavu. \u00DAdajev\u0161ak nazna\u010Duj\u00ED, \u017Ee antiepileptika indukuj\u00EDc\u00ED enzymy zvy\u0161uj\u00ED clearance levetiracetamu u d\u011Bt\u00ED o 20%. D\u00E1vku nen\u00ED nutn\u00E9 upravovat.\nProbenecid:\nBylo zji\u0161t\u011Bno, \u017Ee probenecid (500 mg \u010Dty\u0159ikr\u00E1t denn\u011B), blok\u00E1tor ren\u00E1ln\u00ED tubul\u00E1rn\u00ED sekrece, inhibuje ren\u00E1ln\u00ED clearance prim\u00E1rn\u00EDho metabolitu, ne v\u0161ak levetiracetamu. Koncentrace uveden\u00E9ho metabolitu v\u0161ak z\u016Fst\u00E1v\u00E1 n\u00EDzk\u00E1. Lze o\u010Dek\u00E1vat, \u017Ee ostatn\u00ED l\u00E9\u010Div\u00E9 p\u0159\u00EDpravky vylu\u010Dovan\u00E9 aktivn\u00ED tubul\u00E1rn\u00ED sekrec\u00ED by tak\u00E9 mohly sni\u017Eovat ren\u00E1ln\u00ED clearance metabolitu. \u00DA\u010Dinek levetiracetamu na probenecid nebyl studov\u00E1n a \u00FA\u010Dinek levetiracetamu na dal\u0161\u00ED aktivn\u011B vylu\u010Dovan\u00E9 l\u00E9\u010Div\u00E9 p\u0159\u00EDpravky, nap\u0159. NSA, sulfonamidy a methotrex\u00E1t, nen\u00ED zn\u00E1m.\nPeror\u00E1ln\u00ED kontraceptiva a jin\u00E9 farmakokinetick\u00E9 interakce:\nLevetiracetam v d\u00E1vce 1000 mg denn\u011B nem\u011Bl vliv na farmakokinetiku peror\u00E1ln\u00EDch kontraceptiv (ethinylestradiol a levonorgestrel). Endokrinn\u00ED parametry (luteiniza\u010Dn\u00ED hormon a progesteron) se nezm\u011Bnily. Levetiracetam v d\u00E1vce 2000 mg denn\u011B nem\u011Bl vliv na farmakokinetiku digoxinu ani warfarinu. Protrombinov\u00E9 \u010Dasy se nezm\u011Bnily. Sou\u010Dasn\u00E9 pod\u00E1v\u00E1n\u00ED digoxinu, peror\u00E1ln\u00EDch kontraceptiv ani warfarinu neovlivnilo farmakokinetiku levetiracetamu.\nAntacida:\nNejsou k dispozici \u017E\u00E1dn\u00E9 \u00FAdaje o vlivu antacid na vst\u0159eb\u00E1v\u00E1n\u00ED levetiracetamu.\nJ\u00EDdlo a alkohol:\nRozsah vst\u0159eb\u00E1v\u00E1n\u00ED levetiracetamu nebyl j\u00EDdlem ovlivn\u011Bn, ale rychlost vst\u0159eb\u00E1v\u00E1n\u00ED se m\u00EDrn\u011B sn\u00ED\u017Eila.\nNejsou k dispozici \u017E\u00E1dn\u00E9 \u00FAdaje o interakci levetiracetamu s alkoholem.\n"@cs . . . . . . . . . . . "004.005" . . .